Post-chemo cognitive depreciation linked to brain activity changes

This article originally appeared here.
Share this content:
Post-chemo cognitive depreciation linked to brain activity changes
Post-chemo cognitive depreciation linked to brain activity changes

(HealthDay News) -- For patients undergoing chemotherapy for breast cancer, cognitive complaints after treatment may be associated with changes in brain activity, according to a study published online May 27 in the Journal of Clinical Oncology.

Sabine Deprez, Ph.D., from the Katholieke Universiteit Leuven in Belgium, and colleagues assessed whether cognitive complaints after breast cancer treatment correlate with detectable changes in brain activity during multitasking. A functional magnetic resonance imaging multitasking task was performed in the scanner by 18 patients before the start of chemotherapy treatment (t1) and four to six months after completing treatment (t2). The same task was performed at matched intervals by 16 patients who were not scheduled to receive chemotherapy and 17 matched healthy controls.

The researchers found that, in chemotherapy-treated patients, voxel-based paired t tests revealed significantly decreased activation from t1 to t2 in the multitasking network, but no changes were observed in the control groups. No differences were seen between the groups at baseline. The chemotherapy-treated patients, but not controls, reported a significant increase in cognitive complaints at t2. There were significant associations between these increases and the decrease in multitasking-linked brain activation. There was a significant group-by-time interaction, with chemotherapy-treated patients, but not healthy controls, showing decreased activation.

"These results suggest that changes in brain activity may underlie chemotherapy-induced cognitive complaints," the authors write. "To the best of our knowledge, this is the first longitudinal study providing evidence for a relationship between longitudinal changes in cognitive complaints and changes in brain activation after chemotherapy."

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs